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[The author is a staff writer for the International Weekly Edition of the Gazeta Mercantil, a Sao
Paulo-based financial newspaper.]
In recent years, Brazil has become a leading voice for the developing world. From trade disputes
with the industrialized world regarding sales of regional aircraft to reform of the agreement on
Trade-Related Aspects of Intellectual Property Rights (TRIPS), South America's largest country has
been pushing a Third World agenda that contradicts the role rich, industrialized countries of the
North have outlined for the poor, underdeveloped nations of the South.
The latest conflict between Brazil and the multinational companies based in the US and Europe
has turned into a classic case of "lives vs. profits" the access to AIDS treatment for millions of
poor people versus the need of multinational drug companies to provide millions in profits to
shareholders. To lower treatment costs and provide greater coverage to its HIV-positive population,
Brazil's Health Ministry has threatened to violate patents of state-of-the-art AIDS medication.
In response, Big Pharma large multinational pharmaceutical companies urged the US Trade
Representative (USTR) to request the World Trade Organization (WTO) to investigate Brazilian
legislation governing intellectual property. Brazil has won international support not only for its
highly acclaimed AIDS program, but also for its international diplomatic efforts. Despite strong
resistance from the International Federation of Pharmaceutical Manufacturers Associations (IFPMA)
and the USTR, Brazil's proposal that AIDS medication is a human right have been approved by the
UN Commission on Human Rights and the WHO.
"If we concede a patent and the product is not sold to Brazil, then we have the right to produce it,
paying a royalty," defended Jose Serra, Brazil's Minister of Health and presidential hopeful for the
Partido da Social Democracia Brasiliera (PSDB).

First World treatment in a Third World country
In the 1980s when the AIDS crisis first appeared on the scene, Brazil was expected to be one of
its main targets. "In 1992 the World Bank projected that the country would have over a million
AIDS sufferers by the year 2000," said Dr. Marco Antonio Victoria, chief medical advisor to Brazil's
AIDS program. "This year we have only 200,000 registered cases, and we estimate a total of 540,000
infected people throughout the country." Brazil's remarkably low infection rate of 0.6% of the adult
population is attributed to the willingness by the government and social organizations to fight the
disease head on. Billboards advocating the use of condoms, although condemned by the Catholic
Church, have increased awareness.
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Brazil's low infection rate contrasts with Botswana, which has the highest incidence of HIV
infections in the world at 36%. Recent Health Ministry data also reveals that AIDS- related deaths
dropped 50% between 1995 and 1999. The positive statistics are attributed to the government's
determination to provide free AIDS treatment to those who are infected a necessity in a country in
which 70 million people live below the poverty line. Instead of paying up to US$15,000 a year, the
cost for patient treatment in the US, Brazil decided to produce in government laboratories eight of
the 12 antiretroviral drugs that compose the AIDS "cocktail," which slows the progression from HIV
positive to full-blown AIDS. Not only are patients given a new lease on life, but the government
pays only US$4,400 per patient.
The program pays for itself. "The reduction in the incidence of AIDS-related diseases, an 80%
reduction in hospitalizations, and a need for less treatment has saved the government US$670
million," said Victoria. This year, the Brazilian government hopes to extend treatment to 105,000
people. However, 36% of the program's US$300 million budget goes for two drugs Efavirenz and
Nelfinavir, made by Merck & Co. and Hoffmann-La Roche, respectively.
Recently, the government announced it might violate the patents of the two costly drugs and give
a "compulsory license" to local laboratories to produce them. When government laboratory FarMinguinhos imported the raw material for the two medications from India, multinational drug
companies took the offensive.

Drug companies "bullying" poor countries to accept high prices
After losing the moral battle in South Africa, where 39 large pharmaceutical firms have sued the
government because of its "parallel imports" of cheap, generic copies of AIDS medications, drug
companies urged the US government to request a WTO investigation against Brazil. The stakes are
high since the Brazilian pharmaceutical market is estimated at US$6.5 billion per year.
"We believe Brazilian officials have made some good efforts putting resources toward this major
problem, but they are still part of the world order and need to work things out with our companies,"
said Mark Grayson, spokesman for the Pharmaceutical and Research Manufacturers of America
(PhRMA).
The US asserts that Brazil's patent laws are out of sync with TRIPS. Brazil manufactures the eight
ingredients in the AIDS cocktail because of a loophole in the country's patent legislation, which only
provides intellectual property rights to medicines approved after 1997 when the bill was passed. The
Health Ministry's campaign encouraging consumers to buy generic copies of patented drugs is just
one of the thorns in the side of Big Pharma.
Robert Zoellick, the US trade representative, told the Council of the Americas, a US business
association that promotes hemispheric trade, that the US is not against Brazil's AIDS program but
rather protectionism. The TRIPS accord provides "complete flexibility to allow other countries to
take necessary measures to combat a health tragedy," said Zoellick. What the US was questioning
at the WTO, he said, was the article in Brazil's patent legislation that allows "compulsory licensing"
for any product not produced within the country within three years after being patented. But the US
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has had difficulty shedding the image that it is merely defending the profits of multinational drug
companies.
"The US and the international pharmaceutical companies essentially want countries to buy their
expensive patented products, and they are bullying developing countries to have medicine policies
and patent legislation that further those commercial interests," said Michael Bailey, policy analyst
with the international anti-poverty organization Oxfam.

Brazil goes on the offensive
Unlike smaller nations that often back down when threatened with a WTO investigation, Brazil
organized international support for its case. At the UN Commission on Human Rights meeting in
Geneva, Brazilian diplomats proposed a resolution to ensure "that the application of international
agreements is supportive of public health policies that promote broad access to...affordable
pharmaceuticals and medical technologies." Of the 53 member countries on the commission, 52
voted in favor of the resolution. The US was the only country to abstain.
George Moose, US representative ambassador to the commission, called the motion "bad public
health policy." Last week, Brazil's resolution guaranteeing treatment for AIDS patients was
endorsed by the WHO. IFPMA, however, said that Brazil does not have the capacity to produce good
quality generic medicines. Besides the support of various nation-states, Brazil also has the backing
of many nongovernmental organizations (NGOs).
Oxfam is urging the US to withdraw its WTO case. Having a clause that mandates products be
produced nationally is within the TRIPS accord, argued the organization, since it will only be
invoked in cases of abuse of "economic power" such as high prices charged by drug companies.

Pharmaceutical company makes concessions
Merck has already buckled under the pressure from the Brazilian government and NGOs and
cut the price of Efavirenz by 59% to US$0.89 from US$2.06 for a 200 mg dose. Brazilian officials
are currently negotiating similar price reductions with Roche. Dr. Victoria says drug companies
have a lot of room to reduce prices since as much as "80% to 90% of the cost of medicines goes into
marketing and profits to shareholders."
The pharmaceutical industry warns that patent violations will have serious repercussions in future
care. "If every time there is an epidemic a patent is violated, companies will not get a return on
their investments and then will stop selling their products in countries where there is a threat of
violating a patent," said Jose Eduardo Bandeira de Mello, president of the Brazilian Association of
Pharmaceutical Industries (ABIFARMA). IFPMA has also threatened to stop investing in countries
that do not respect intellectual property rights.
Another concern for the drug industry is that, if prices are slashed in the developing world,
consumers in rich countries will also demand price cuts or seek cheaper copies in the gray market.
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Drug companies, watching their profits drop, will then have fewer incentives to pour money into
research and development for an AIDS vaccine.
Oxfam's Bailey believes a differentiated price system is still possible and patent protection is a
valid argument in rich countries, which provide most of the drug companies' market. The case for
intellectual property in poor countries, he says, is quite different. "Tough patents in developing
countries certainly generate high profits, but there is no evidence that it will generate more
research," said Bailey.

Need for global fund for AIDS treatment
Access to life-saving medication for the needy has finally reached the agenda of multilateral
organizations like the World Bank and G-7/8 meetings of the leaders of industrialized countries.
One proposal is to create a fund to finance research and the purchase of medication from drug
companies. Haste is needed to avoid an international catastrophe as less than 5% of those infected
with HIV have access to adequate treatment.
What UN General Secretary Kofi Annan calls "the greatest public health challenge of our times"
has already claimed the lives of 16.3 million people and currently infects 33.6 million worldwide.
"If the South African government had been able to afford a similar package of care as that given to
HIV/AIDS sufferers in Brazil, over 300,000 lives could have been saved since the court case [in South
Africa] began three years ago," said Bailey.

-- End --
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